[Oral antidiabetic agents including glucosidase inhibitors].
Raptis
S
S
D000284:Administration, Oral; D001645:Biguanides / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D003925:Diabetic Angiopathies / Q000188:drug therapy; D005959:Glucosidases / Q000037:antagonists & inhibitors*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D011972:Receptor, Insulin / Q000187:drug effects; D013453:Sulfonylurea Compounds / Q000627:therapeutic use
D001645:Biguanides; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D011972:Receptor, Insulin; D005959:Glucosidases
Orale Antidiabetika einschliesslich Glucosidasehemmern.